Skip to main content
CSL Ltd. logo

CSL Ltd. — Investor Relations & Filings

Ticker · CSL ISIN · AU000000CSL8 LEI · 529900ECSECK5ZDQTE14 ASX Manufacturing
Open in API
Filings indexed 2,559 across all filing types
Latest filing 2026-06-09 Share Issue/Capital Cha…
Country AU Australia
Listing ASX CSL

About CSL Ltd.

https://www.csl.com/

CSL is a global biotechnology company that researches, develops, manufactures, and markets a diverse portfolio of medicines. The company operates through distinct business units. CSL Behring provides plasma-derived and recombinant biotherapies for patients with rare and serious diseases, including bleeding disorders, immunodeficiencies, and neurological disorders. CSL Seqirus is a leading provider of vaccines, with a focus on influenza prevention and public health. CSL Vifor specializes in therapies for iron deficiency and nephrology, addressing the full spectrum of kidney disease. Collectively, CSL delivers lifesaving and life-enhancing treatments to a global patient population.

Recent filings

Filing Released Lang Actions
Notification of cessation of securities - CSL 4 pages 14.6KB
Share Issue/Capital Change Classification · 88% confidence The document is an ASX Appendix 3H form notifying the cessation (lapse) of unquoted securities (rights) and the resulting changes in issued capital. This is a formal announcement of a capital structure change. Under FinancialReports taxonomy, such announcements fall under ‘Share Issue/Capital Change’ (SHA).
2026-06-09 English
Appendix 3Y - Carolyn Hewson AO 3 pages 232.5KB
Director's Dealing Classification · 98% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' filed under ASX Listing Rule 3.19A.2. It details a director’s acquisition and disposal of securities, reporting changes in relevant interests in shares and rights. This matches the definition of a Director’s Dealing report.
2026-06-05 English
Amended Appendix 3Y - Gordon Naylor 4 pages 317.7KB
Director's Dealing Classification · 95% confidence The document is an Appendix 3Y Change of Director’s Interest Notice filed with the ASX, detailing the acquisition of shares by a director (Gordon Naylor) and correcting a previously lodged notice. This is a classic insider director dealing report under ASX listing rules. Therefore, it falls under Director's Dealing (Code: DIRS).
2026-05-27 English
Appendix 3Y - Gordon Naylor 3 pages 231.2KB
Director's Dealing Classification · 95% confidence The document is ASX Appendix 3Y, a Change of Director’s Interest Notice reporting a director’s personal share transactions and interests as required under Listing Rule 3.19A.2. This corresponds to insider share dealings by a director. Therefore, it fits the Director’s Dealing category.
2026-05-27 English
Appendix 3Y - Alison Watkins 3 pages 232.1KB
Director's Dealing Classification · 85% confidence The document is ASX Appendix 3Y ‘Change of Director’s Interest Notice’, listing a director’s acquisition of shares, their indirect interests, and trade details under Listing Rule 3.19A.2. This is a notification of insider share transactions by a director and falls under Director’s Dealing.
2026-05-17 English
Interim CEO 90 Day Review and Financial Update 23 pages 1.6MB
Investor Presentation Classification · 90% confidence The document is an ASX announcement containing a presentation and slides to investors with detailed financial outlook, strategic initiatives, and a webcast link. It is not simply a brief notice of report publication nor a full statutory interim report; rather it provides a full investor slide deck and commentary. This matches the definition of an Investor Presentation (Code: IP).
2026-05-10 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.